Document Detail


Transcriptional down regulation of hTERT and senescence induction in HepG2 cells by chelidonine.
MedLine Citation:
PMID:  19653337     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: To investigate the potential effects of chelidonine, the main alkaloid of Chelidonium majus, on telomerase activity and its regulation in HepG2 cells. METHODS: Cytotoxicity of chelidonine for HepG2 cells was determined by neutral red assay. A modified polymerase chain reaction (PCR)-based telomerase repeat amplification protocol was used to estimate relative telomerase activity in chelidonine-treated cells in comparison with the untreated control cells. Relative expression level of the catalytic subunit of telomerase (hTERT) gene and P-glycoprotein (pgp) were estimated using semi-quantitative real-time reverse transcription-PCR (RT-PCR). Cell senescence in treated cells was demonstrated using a beta-galactosidase test. RESULTS: Cytotoxicity of chelidonine in HepG2 cells was not dose-dependent and tended to reach plateau immediately after the living cells were reduced in number to slightly higher than 50%. However, 12 micromol/L concentration of chelidonine was considered as LD(50), where the maximal attainable effects were realized. Real-time RT-PCR data showed that the expression of pgp increased three-fold in chelidonine treated HepG2 cells in comparison with the untreated controls. Morphologically, treated HepG2 cells showed apoptotic features after 24 h and a small fraction of cells appeared with single blister cell death. The relative expression level of Bcl-2 dropped to less than 50% of control cells at a sub-apoptotic concentration of chelidonine and subsequently increased to higher than 120% at LD(50). Telomerase activity was reduced considerably after administration of very low doses of chelidonine, whereas higher concentrations of chelidonine did not remarkably enhance the effect. Real-time RT-PCR experiments indicated a drastic decrease in expression level of hTERT subunit of telomerase under treatment with chelidonine. Repeated treatment of cells with very low doses of chelidonine caused a decline in growth rate by 4 wk and many of the cells appeared to be aged with large volume and dark staining in the beta-galactosidase assay. CONCLUSION: Chelidonine reduces telomerase activity through down-regulation of hTERT expression. Senescence induction might not be directly caused by reducing telomerase activity as it occurs after a few population doublings.
Authors:
Sakineh Kazemi Noureini; Michael Wink
Related Documents :
8536797 - Methodologic considerations for the use of canine in vivo aged biotinylated erythrocyte...
15133297 - Delayed induction of telomere instability in normal human fibroblast cells by ionizing ...
15354417 - Effect of all-trans retinoic acid on telomerase activity in ovarian cancer cells.
11748027 - A biologically based model of growth and senescence of syrian hamster embryo (she) cell...
17571237 - High expression of integrin beta1 correlates with high proliferation capacity in oral k...
15524167 - Autophagy: many paths to the same end.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  World journal of gastroenterology : WJG     Volume:  15     ISSN:  1007-9327     ISO Abbreviation:  World J. Gastroenterol.     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-08-04     Completed Date:  2009-12-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883448     Medline TA:  World J Gastroenterol     Country:  China    
Other Details:
Languages:  eng     Pagination:  3603-10     Citation Subset:  IM    
Affiliation:
Department of Biology, Faculty of Basic Sciences, Tarbiat Moallem University of Sabzevar, Sabzevar, Iran. s-kazemi@sttu.ac.ir
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents, Phytogenic / analysis
Apoptosis / drug effects
Benzophenanthridines / pharmacology*
Cell Aging / drug effects
Cell Line, Tumor
Chelidonium / chemistry
Down-Regulation / drug effects
Genes, bcl-2 / drug effects
Humans
P-Glycoprotein / metabolism
Proto-Oncogene Proteins c-bcl-2 / metabolism
Telomerase / metabolism*
beta-Galactosidase / metabolism
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/Benzophenanthridines; 0/P-Glycoprotein; 0/Proto-Oncogene Proteins c-bcl-2; 476-32-4/chelidonine; EC 2.7.7.49/TERT protein, human; EC 2.7.7.49/Telomerase; EC 3.2.1.23/beta-Galactosidase
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Irinotecan therapy and molecular targets in colorectal cancer: A systemic review.
Next Document:  Phenotypic changes of human cells in human-rat liver during partial hepatectomy-induced regeneration...